Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

AstraZeneca wins positive CHMP opinion for Imfinzi for unresectable or metastatic biliary tract cancer

By Brian Buntz | November 16, 2022

AstraZeneca in the Drug Discovery & Development Pharma 50Cambridge, UK–based AstraZeneca (Nasdaq:AZN) has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended a new marketing authorization of Imfinzi (durvalumab).

The recommendation specifically refers to the first-line treatment of adults with unresectable or metastatic biliary tract cancer (BTC) in combination with chemotherapy (gemcitabine with cisplatin).

In an interim analysis, durvalumab with chemotherapy was associated with a 20% reduction in the risk of death compared to chemotherapy as a monotherapy.

The TOPAZ-1 study found a 24% reduction in the risk of death compared to chemotherapy alone after an additional 6.5 months. In addition, the company estimates that twice as many patients of durvalumab and chemotherapy were alive at two years compared to those on chemotherapy alone.

AstraZeneca notes that durvalumab was generally well tolerated in the TOPAZ-1 study. A total of 60.9% of patients treated with Imfinzi and chemotherapy had Grade 3 or 4 treatment-related adverse events. In the chemotherapy-only arm, 63.5% of patients had Grade 3 or 4 adverse events.

“If approved, Imfinzi plus chemotherapy will provide patients with advanced biliary tract cancer the first opportunity for treatment with an immunotherapy-based combination,” said Susan Galbraith, executive vice president of oncology R&D of AstraZeneca, in a news release. “This innovative regimen has been shown to significantly prolong patients’ lives, and we look forward to bringing this option to those in the European Union as soon as possible.”

Durvalumab with chemotherapy is already approved in several regions for locally advanced or metastatic BTC, including the U.S., Canada, South Korea and Brazil.

In 2018, the EMA approved durvalumab as monotherapy for locally-advanced, unresectable non-small cell lung cancer (NSCLC) in adults with tumors expressing PD-L1 on at least 1% of tumor cells. That approval covered patients with cancer that had not progressed after platinum-based chemotherapy and radiation therapy (CRT).

AstraZeneca shares on the Nasdaq were mostly flat, hovering around $63.95.


Filed Under: Oncology
Tagged With: AstraZeneca, Imfinzi
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Labcorp widens precision oncology toolkit, aims to speed drug-trial enrollment
AP Biosciences charts course for safer CD137 bispecifics with its T-cube platform
Cellares and UW-Madison partner to automate manufacturing for novel solid tumor CAR-T
Why smaller, simpler molecular glues are gaining attention in drug discovery
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE